New data demonstrate clinical benefit of Roche’s glofitamab
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Includes thermostabilized Ebola vaccines
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Subscribe To Our Newsletter & Stay Updated